Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11089854 | PMC |
| http://dx.doi.org/10.1177/19322968241235218 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: Tau-PET tracers allow for in vivo Braak staging of individuals in the Alzheimer's disease (AD) continuum. The impact of tracers' characteristics for Braak staging using tau-PET remains unclear. Therefore, we performed a head-to-head comparison of Braak staging using first- and second-generation tau-PET tracers.
View Article and Find Full Text PDFBiomarkers.
Alzheimers Dement
December 2024
Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, Lund, Sweden.
Background: We assessed the efficacy of four plasma phospho-tau217 (p-tau217) biomarkers in a head-to-head comparison, and against two clinically available CSF biomarkers for Alzheimer's disease (AD).
Method: Samples were analyzed from 1009 individuals from the Swedish BioFINDER-2 cohort (Table 1). We included the following biomarkers: %p-tau217, p-tau217 (both mass-spectrometry), p-tau217, p-tau217 (both immunoassays), CSF p-tau181 and p-tau181/Aβ42 (Elecsys).
Biomarkers.
Alzheimers Dement
December 2024
Translational Neuroimaging Laboratory, The McGill University Research Centre for Studies in Aging, Montréal, QC, Canada.
Background: To evaluate the in vitro binding properties of [C]PiB and [F]NAV4694 head-to-head in post-mortem human brain tissue.
Method: Autoradiography was used to assess uptake of [C]PiB and [F]NAV4694 in control (CN) and Alzheimer's disease (AD) autopsy-confirmed brain tissues. The study focuses on the analysis of the prefrontal cortex, inferior parietal cortex, posterior cingulate cortex and hippocampus sections in 11 CN and 11 AD cases.
Biomarkers.
Alzheimers Dement
December 2024
Alzheimer Center Amsterdam, Amsterdam UMC, Amsterdam, Netherlands.
Background: Tau-PET is a diagnostic tool with high sensitivity and high specificity for discriminating Alzheimer Disease (AD) dementia from other neurodegenerative disorders in well-controlled research environments. The role of tau-PET in "real-world" clinical practice, however, remains to be established. We hypothesize that tau-PET will lead to some changes of the pre-PET clinical diagnosis and will improve diagnostic certainty and patient management in patients with considerable diagnostic uncertainty.
View Article and Find Full Text PDFBackground: The ability to quantify pathogenic proteins related to Alzheimer's disease (AD) in plasma neuronal extracellular vesicles (NEVs) was vital to their development as diagnostic biomarkers. A similar approach can be employed to assess the biomarker potential of saliva EVs. A head-to-head comparison was conducted to characterize plasma and saliva EVs derived patients enrolled in the Nathan Shock Healthy Aging Study, where participants range in age from 30-70+ years, representing the full breadth of the healthy adult human age span.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!